Merck GSK8815

GSK8815

≥98% (HPLC)

8-[[(3S,4S,5R)-3-[(4,4-Difluorocyclohexyl)methoxy]-5-methoxy-4-piperidinyl]amino]-3-methyl-5-(5-methyl-3-pyridinyl)-1,7-naphthyridin-2(1H)-one, 8-((3S,4S,5R)-3-((4,4-Difluorocyclohexyl)methoxy)-5-methoxypiperidin-4-ylamino)-3-methyl-5-(5-methylpyridin-3-yl)-1,7-naphthyridin-2(1H)-one

assay

≥98% (HPLC)

form

powder

색상

white to beige

solubility

DMSO: 2 mg/mL, clear

저장 온도

−20°C

SMILES string

O=C(N1)C(C)=CC2=C1C(N[C@H]3[C@H](OCC4CCC(F)(F)CC4)CNC[C@H]3OC)=NC=C2C5=CN=CC(C)=C5

GSK8815 is an aqueous soluble (326 μM) naphthyridone that serves as a negative control for the more active diastereomer GSK8814 in ATAD2/ATAD2B inhibition studies. Comparing to GSK8814, GSK8815 is ineffective in cell-based assays and exhibits greatly reduced affinity toward ATAD2 & ATAD2B bromodomain in cell-free binding assays (pKd for ATAD2 = 5.5/GSK8815 vs. 8.1/GSK8814 by ITC; pIC50 against ATAD2 BD/ATAD2B BD = 5.5/5.5 with GSK8815 vs. 7.3/7.7 with GSK8814 in competitive ligand binding assays by TR-FRET).